ArriVent BioPharma
AVBP
16.89
+1.80
+11.93%
ArriVent BioPharma
US · AVBP
#3057 by market cap
Listed 2024
16.89
+1.80
+11.93%
Live - 5344 symbols - heartbeat 484s ago
· 2026-10-08 07:24
Pre-market
16.74
-0.88%
After-hours
17.10
+1.24%
Overnight
16.89
0.00%
- Market cap
- 832.81M
- P/E (TTM)i
- -4.76
- P/Bi
- 2.27
- EPSi
- -4.32
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on AVBP?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 5 years
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 6.47M | 9.71M | 15.30M | 24.18M |
| Research & development | -- | 30.43M | 64.88M | 79.00M | 153.35M |
| Operating profit | -- | -36.91M | -74.59M | -94.31M | -177.53M |
| Pretax profit | -- | -36.91M | -69.33M | -80.49M | -166.31M |
| Tax | -- | -- | -- | -- | -- |
| Net profit | -- | -36.91M | -69.33M | -80.49M | -166.31M |
| Basic EPS | -- | -1 | -2 | -3 | -4 |
| Diluted EPS | -- | -1.15 | -2.17 | -2.56 | -4.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.48M | 5.90M | 6.15M | 6.65M | 8.49M | 10.35M |
| Research & development | 61.29M | 27.72M | 32.17M | 32.18M | 37.62M | 42.34M |
| Operating profit | -66.77M | -33.62M | -38.32M | -38.82M | -46.11M | -52.69M |
| Pretax profit | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M | -49.89M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M | -49.89M |
| Basic EPS | -2 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.90 | -0.90 | -0.83 | -0.78 | -0.96 | -1.05 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.90M |
| Cash & ST investments | 37.28M | 163.37M | 150.39M | 218.86M | 312.82M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | 43.04M | 182.83M | 163.10M | 274.94M | 333.17M |
| Total current liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Short-term debt | -- | 128.00K | 140.00K | 162.00K | 14.00K |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 1,818,000.00 | 267,942,000.00 | 316,291,000.00 | 17,288,000.00 | 25,945,000.00 |
| Total equity | 41.22M | -85.11M | -153.19M | 257.65M | 307.22M |
| Retained earnings | -51.61M | -88.51M | -157.85M | -238.33M | -404.64M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 185.79M | 250.15M | 321.22M | 332.90M | 348.70M | 394.17M |
| Cash & ST investments | 176.08M | 235.69M | 300.27M | 312.82M | 326.38M | 373.12M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 215.50M | 269.51M | 326.56M | 333.17M | 349.30M | 394.72M |
| Total current liabilities | 12.95M | 19.64M | 21.56M | 25.95M | 25.00M | 27.84M |
| Short-term debt | 138.00K | 98.00K | 56.00K | 14.00K | 99.00K | 318.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 12,953,000.00 | 19,636,000.00 | 21,558,000.00 | 25,945,000.00 | 25,315,000.00 | 27,877,000.00 |
| Total equity | 202.54M | 249.87M | 305.00M | 307.22M | 323.98M | 366.84M |
| Retained earnings | -302.72M | -334.12M | -369.10M | -404.64M | -447.96M | -497.85M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -- | -43.63M | -55.84M | -70.21M | -160.59M |
| Depreciation & amortization | -- | -- | -- | -- | -- |
| Free cash flow | -- | -43.63M | -55.84M | -70.21M | -160.59M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 2.00K | 0 | 185.95M | 202.63M |
| Ending cash balance | -- | 163.37M | 150.39M | 74.29M | 45.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -68.01M | -26.12M | -35.80M | -30.66M | -41.89M | -39.58M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -68.01M | -26.12M | -35.80M | -30.66M | -41.89M | -39.58M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 6.52M | 75.34M | 86.12M | 34.66M | 54.72M | 85.24M |
| Ending cash balance | 49.87M | 112.77M | 112.67M | 45.54M | 62.10M | 154.68M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -154.10 | -58.88 |
| ROA %i | -- | -32.68 | -40.08 | -36.75 | -54.70 |
| ROIC %i | -- | -- | -- | -179.71 | -62.84 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 23.63 | 21.84 | 13.76 | 13.14 | 12.83 |
| Quick ratioi | 20.64 | 19.60 | 13.00 | 12.70 | 12.06 |
| Debt / assetsi | 0.00 | 0.08 | 0.19 | 0.06 | 0.00 |
| LT debt / equityi | -- | -- | -- | 0.01 | -- |
| Interest coveragei | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -49.00 | -50.13 | -199.46 | -58.88 | -55.17 | -53.10 |
| ROA %i | -46.92 | -47.37 | -61.84 | -54.70 | -51.43 | -49.30 |
| ROIC %i | -53.93 | -54.25 | -213.46 | -62.84 | -59.53 | -57.02 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 14.34 | 12.74 | 14.90 | 12.83 | 13.95 | 14.16 |
| Quick ratioi | 13.63 | 12.03 | 13.95 | 12.06 | 13.06 | 13.40 |
| Debt / assetsi | 0.06 | 0.04 | 0.02 | 0.00 | 0.12 | 0.09 |
| LT debt / equityi | -- | -- | -- | -- | 0.10 | 0.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:24:58 · For reference only, not investment advice and not tailored to your situation.